Mark J. Mulligan

Active 1986–2025

Also published as
Mark J Mulligan
121
Papers
22,430
Citations
70
h-index
114
i10-index

Citations

Citations per year for Mark J. Mulligan1988: 2 citations1990: 1 citations1991: 1 citations1992: 3 citations1993: 5 citations1994: 13 citations1995: 11 citations1996: 16 citations1997: 16 citations1998: 26 citations1999: 30 citations2000: 22 citations2001: 29 citations2002: 43 citations2003: 33 citations2004: 50 citations2005: 26 citations2006: 40 citations2007: 31 citations2008: 28 citations2009: 53 citations2010: 68 citations2011: 93 citations2012: 98 citations2013: 110 citations2014: 116 citations2015: 166 citations2016: 163 citations2017: 233 citations2018: 219 citations2019: 611 citations2020: 851 citations2021: 2,171 citations2022: 1,432 citations2023: 581 citations2024: 737 citations2025: 342 citations2026: 13 citations1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,696 citing papers, 31.3% of this breakdownChina: 821 citing papers, 7% of this breakdownUnited Kingdom: 804 citing papers, 6.8% of this breakdownGermany: 514 citing papers, 4.4% of this breakdownItaly: 387 citing papers, 3.3% of this breakdownCanada: 357 citing papers, 3% of this breakdownFrance: 354 citing papers, 3% of this breakdownAustralia: 332 citing papers, 2.8% of this breakdownSwitzerland: 270 citing papers, 2.3% of this breakdownNetherlands: 263 citing papers, 2.2% of this breakdownIndia: 247 citing papers, 2.1% of this breakdownBrazil: 206 citing papers, 1.8% of this breakdown
0%31.3%Other 30%

Fields

  • Medicine65.2%
  • Immunology and Microbiology17.1%
  • Biochemistry, Genetics and Molecular Biology10.9%
  • Pharmacology, Toxicology and Pharmaceutics2.9%
  • Social Sciences0.8%
  • Mathematics0.5%
  • Other2.6%

Topics

  • SARS-CoV-2 and COVID-19 Research14.2%
  • COVID-19 Clinical Research Studies6.8%
  • Immunotherapy and Immune Responses4.2%
  • vaccines and immunoinformatics approaches3.6%
  • Immune Cell Function and Interaction3.4%
  • HIV Research and Treatment2.8%
  • Other65%

Coauthors

All papers

Open in search
  1. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 2,730

  2. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2020 cited by 1,594

  3. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Immunology 2013 cited by 803

  4. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tina Tong, Margaret Brewinski Isaacs, David Benkeser, Holly E. Janes, Martha C. Nason, Justin A. Green, Elizabeth J. Kelly, Jill Maaske, Nancy Mueller, Kathryn Shoemaker, Therese Takas, Richard P. Marshall, Menelas N. Pangalos, Tonya Villafana, Antonio Gonzalez-Lopez - New England Journal of Medicine 2021 cited by 683

  5. Homologous and Heterologous Covid-19 Booster Vaccinations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adrian B. McDermott, Sarah O’Connell, David C. Montefiori, Amanda Eaton, Kathleen M. Neuzil, David S. Stephens, Paul C. Roberts, John H. Beigel - New England Journal of Medicine 2022 cited by 618

  6. Origin and differentiation of human memory CD8 T cells after vaccination

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 533

  7. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 cited by 424

  8. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Franz J. Triana, J. Hendle, Anna Pustilnik, Andrew C. Adams, Shawn Berens, Ralph S. Baric, David R. Martinez, Robert W. Cross, Thomas W. Geisbert, Viktoriya Borisevich, Olubukola M. Abiona, Hayley M. Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, Marie I. Samanovic, Mark J. Mulligan, Jory A. Goldsmith, Ching‐Lin Hsieh, Nicole V. Johnson, Daniel Wrapp, Jason S. McLellan, Bryan C. Barnhart, Barney S. Graham, John R. Mascola, Carl L. Hansen, Ester Falconer - Science Translational Medicine 2021 cited by 497

  9. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Immunology 2008 cited by 1,122

  10. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 585

  11. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Vaccine 2015 cited by 148

  12. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2011 cited by 802

  13. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David S. Stephens, Diane J. Post, Seema Nayak, Mehul S. Suthar, Paul C. Roberts, John H. Beigel, David C. Montefiori, Jennifer Husson, Angie Price, Jennifer A. Whitaker, Wendy A. Keitel, Ann R. Falsey, Ian Shannon, Daniel S. Graciaa, Nadine Rouphael, Evan J. Anderson, Satoshi Kamidani, Gysella Muñiz, Sonika Bhatnagar, Anna Wald, Megan Berman, Laura Porterfield, Amber Stanford, Jennifer Lee Dong, Steven E. Carsons, Diana Badillo, Susan Parker, Michelle Dickey, Sasha E. Larsen, John Hural, Brian Ingersoll, Marina Lee, Lilin Lai, Katharine Floyd, Madison Ellis, Kathryn M. Moore, Kelly E. Manning, Stephanie L. Foster, Mit Patel - Cell Reports Medicine 2022 cited by 167

  14. Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures

    Authors: , , , , , , , , , , , , , , , , , - Immunity 2015 cited by 345

  15. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barney S. Graham, Theodore C. Pierson, Julie E. Ledgerwood, Grace Chen, Sarah H. Plummer, Pamela Costner, Kathryn L. Zephir, Joseph P. Casazza, Abidemi Ola, Milalynn Victorino, Carol Levinson, William Whalen, Xiaolin Wang, Jennifer Cunningham, Olga Vasilenko, Maria Burgos Florez, Somia P. Hickman, Iris Pittman, Lam Le, Brenda Larkin, Charla Andrews, Preeti Apte, Renunda Hicks, Cora Trelles Cartagena, Pernell Williams, Catina Boyd, Michelle Conan-Cibotti, Judy Stein, Florence Kaltovich, Hope DeCederfelt, Stacey McAdams, Phyllis Renehan, Wilbur Chen, Nancy Greenberg, Nancy Wymer, Linda Wadsworth, Melissa Billington, Toni Robinson, Colleen Boyce, Faith Pa'ahana Brown, Lisa Chrisley, Alyson Kwon, Prashant Patel, Panagoita Kominou, Brenda Dorsey, Staci Eddington, Shinyi Telscher, Myoughee Lee, Regina Mosely, April Ross, Geoffrey Ford, Briyana Domjahn, Jianguo Xu, Allison Beck, Rebecca Fineman, Shiela Heeke, Jean M. Winter, Shashi Nagar, Colleen F. Kelley, Mark J. Mulligan, Sarah H. Plummer, Pamela Costner, Kathryn L. Zephir, Joseph P. Casazza, Abidemi Ola, Milalynn Victorino, Carol Levinson, William Whalen, Xiaolin Wang, Jennifer Cunningham and 18 more - The Lancet 2017 cited by 304

  16. Metabolic Phenotypes of Response to Vaccination in Humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2017 cited by 288

  17. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans

    Authors: , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 245

  18. Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines

    Authors: , , , , , , , , , , , , , , , , - Immunity 2008 cited by 613

  19. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

    Authors: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 598

  20. The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response

    Authors: , , , , , , , , , , , , , , , - The Journal of Immunology 2009 cited by 349

  21. The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention

    Authors: , , , , , , , , , , , - Mucosal Immunology 2016 cited by 191

  22. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 89

  23. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karen Price, Janelle Sabo, Jay Tuttle, Paul Klekotka, Lei Shen, Daniel Skovronsky, BLAZE-2 Investigators, Kwadwo-Agyei Gyamfi, Jason Begue, Scott Borgetti, Greer Burkholder, Srilatha Edupuganti, Kathleen Gannon, Christopher J. Hall, V. G. Horstman, Rubaba Hussain, Leandro Mena, Tina Merritt, C. Brendan Montano, Jason Morris, Meenakshi Patel, Ayesha Rashid, H. J. Solomon, Mousumi Som, George Taffet - JAMA 2021 cited by 208

  24. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity

    Authors: , , , , , , - Vaccine 2020 cited by 72